Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal

Frederick W. Thielen*, Nasuh C. Bueyuekkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen, Isaac Corro Ramos

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)975-984
Number of pages10
JournalPharmacoeconomics
Volume37
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • GROUP PERSPECTIVE

Cite this

Thielen, Frederick W. ; Bueyuekkaramikli, Nasuh C. ; Riemsma, Rob ; Fayter, Debra ; Armstrong, Nigel ; Wei, Ching-Yun ; Carrera, Vanesa Huertas ; Misso, Kate ; Worthy, Gill ; Kleijnen, Jos ; Ramos, Isaac Corro. / Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 8. pp. 975-984.
@article{8598a321a3c5459eb47b0ccd22edb52e,
title = "Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal",
keywords = "GROUP PERSPECTIVE",
author = "Thielen, {Frederick W.} and Bueyuekkaramikli, {Nasuh C.} and Rob Riemsma and Debra Fayter and Nigel Armstrong and Ching-Yun Wei and Carrera, {Vanesa Huertas} and Kate Misso and Gill Worthy and Jos Kleijnen and Ramos, {Isaac Corro}",
year = "2019",
month = "8",
doi = "10.1007/s40273-018-0740-4",
language = "English",
volume = "37",
pages = "975--984",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "8",

}

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal. / Thielen, Frederick W.; Bueyuekkaramikli, Nasuh C.; Riemsma, Rob; Fayter, Debra; Armstrong, Nigel; Wei, Ching-Yun; Carrera, Vanesa Huertas; Misso, Kate; Worthy, Gill; Kleijnen, Jos; Ramos, Isaac Corro.

In: Pharmacoeconomics, Vol. 37, No. 8, 08.2019, p. 975-984.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma

T2 - An Evidence Review Group Evaluation of the NICE Single Technology Appraisal

AU - Thielen, Frederick W.

AU - Bueyuekkaramikli, Nasuh C.

AU - Riemsma, Rob

AU - Fayter, Debra

AU - Armstrong, Nigel

AU - Wei, Ching-Yun

AU - Carrera, Vanesa Huertas

AU - Misso, Kate

AU - Worthy, Gill

AU - Kleijnen, Jos

AU - Ramos, Isaac Corro

PY - 2019/8

Y1 - 2019/8

KW - GROUP PERSPECTIVE

U2 - 10.1007/s40273-018-0740-4

DO - 10.1007/s40273-018-0740-4

M3 - Review article

VL - 37

SP - 975

EP - 984

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 8

ER -